Drug:
Reaction: CONDITION AGGRAVATED
20260101 - 20261231
No. 101 - 200
| No. | safetyreportid |
occurcountry |
patientonsetage |
patientsex 1:M 2:F |
|---|---|---|---|---|
Adverse reaction |
||||
Drug (openfda.generic_name, medicinalproduct) |
||||
| 101 | 26551625 |
CA |
61 | 2 |
Suicidal ideation, Condition aggravated, |
||||
PANTOPRAZOLE, VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE, VENLAFAXINE HYDROCHLORIDE, VENLAFAXINE, IRBESARTAN, |
||||
| 102 | 26551635 |
VN |
1 | |
Myelosuppression, Pneumonia, Respiratory distress, Condition aggravated, Anaemia, Otitis media, Thrombocytopenia, Off label use, |
||||
GANCICLOVIR SODIUM, GANCICLOVIR, VALGANCICLOVIR HYDROCHLORIDE, VALGANCICLOVIR, VALGANCICLOVIR HYDROCHLORIDE POWDER,, VALGANCICLOVIR HYDROCHLORIDE, VALGANCICLOVIR, VALGANCICLOVIR HYDROCHLORIDE POWDER,, AMPICILLIN, AMPICILLIN SODIUM, AMPICILLIN INJECTION, GENTAMICIN, GENTAMICIN SULFATE, CEFOTAXIME, CEFOTAXIME INJECTION, ACYCLOVIR, MEROPENEM, |
||||
| 103 | 26551862 |
US |
2 | |
Macular degeneration, Ocular discomfort, Condition aggravated, |
||||
OSIMERTINIB, |
||||
| 104 | 26551869 |
US |
||
Product ineffective, Condition aggravated, |
||||
ANIFROLUMAB-FNIA, |
||||
| 105 | 26551946 |
US |
78 | 1 |
Hallucination, Delusion, Balance disorder, Condition aggravated, Anxiety, Depression, Incoherent, Dysarthria, Confusional state, Fall, |
||||
PIMAVANSERIN TARTRATE, |
||||
| 106 | 26551991 |
CA |
56 | 2 |
Immune system disorder, Condition aggravated, |
||||
CYCLOSPORINE, |
||||
| 107 | 26552231 |
92 | 2 | |
Condition aggravated, Dizziness, |
||||
IBUPROFEN, IBUPROFEN CAPSULES 200 MG, IBUPROFEN TABLETS USP, 200MG, IBUPROFEN TABLET, FILM COATED, IBUPROFEN ORAL, IBUPROFEN 200MG, IBUPFROFEN, IBUPROFEN TABLET, FILM-COATED, IBUPROFEN 200 MG, IBUPROFEN CAPSULE, |
||||
| 108 | 26552325 |
US |
||
Condition aggravated, Drug ineffective, |
||||
PREDNISOLONE ACETATE, |
||||
| 109 | 26552453 |
AU |
14 | 1 |
Gastrointestinal disorder, Condition aggravated, |
||||
QUETIAPINE FUMARATE, QUETIAPINE, MELATONIN, |
||||
| 110 | 26552458 |
EU |
51 | 1 |
Quality of life decreased, Tinnitus, Immunisation reaction, Condition aggravated, Dizziness, Depression, Drug ineffective, Muscle rigidity, |
||||
QUETIAPINE FUMARATE, QUETIAPINE, LEVODOPA, TIZANIDINE, |
||||
| 111 | 26552510 |
EU |
44 | 1 |
Graft loss, Lupus nephritis, Condition aggravated, |
||||
TACROLIMUS, TACROLIMUS OINTMENT 0.1%, TACROLIMUS EXTENDED-RELEASE CAPSULES, MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL HYDROCHLORIDE, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, AZATHIOPRINE, |
||||
| 112 | 26552511 |
EU |
27 | 2 |
Lupus nephritis, Condition aggravated, |
||||
TACROLIMUS, TACROLIMUS OINTMENT 0.1%, TACROLIMUS EXTENDED-RELEASE CAPSULES, MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL HYDROCHLORIDE, AZATHIOPRINE, |
||||
| 113 | 26552513 |
EU |
16 | 2 |
Transplant dysfunction, Transplant failure, Lupus nephritis, Condition aggravated, |
||||
TACROLIMUS, TACROLIMUS OINTMENT 0.1%, TACROLIMUS EXTENDED-RELEASE CAPSULES, MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL HYDROCHLORIDE, CYCLOSPORINE, AZATHIOPRINE, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, |
||||
| 114 | 26552515 |
EU |
14 | 2 |
Lupus nephritis, Condition aggravated, |
||||
TACROLIMUS, TACROLIMUS OINTMENT 0.1%, TACROLIMUS EXTENDED-RELEASE CAPSULES, MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL HYDROCHLORIDE, CYCLOPHOSPHAMIDE FOR INJECTION, CYCLOPHOSPHAMIDE, CYCLOPHOSPHAMIDE INJECTION, SOLUTION, |
||||
| 115 | 26552621 |
US |
1 | |
Gait disturbance, Condition aggravated, Overdose, Dyspnoea, |
||||
| 116 | 26552949 |
AU |
68 | 1 |
Raynaud^s phenomenon, Condition aggravated, |
||||
SILDENAFIL CITRATE, SILDENAFIL, NIFEDIPINE, |
||||
| 117 | 26553030 |
US |
88 | 1 |
Condition aggravated, Drug ineffective, Incorrect product administration duration, |
||||
DEXTROMETHORPHAN HYDROBROMIDE,GUAIFENESIN, DEXTROMETHORPHAN HYDROBROMIDE,GUAIFENESIN, GABAPENTIN, ACETAMINOPHEN, GUAIFENESIN, AND PHENYLEPHRINE HYDROCHLORIDE, ACETAMINOPHEN, ACETAMINOPHEN, GUAIFENESIN, AND PHENYLEPHRINE HYDROCHLORIDE, ACETAMINOPHEN, |
||||
| 118 | 26553114 |
GB |
78 | 1 |
Chronic kidney disease, Acute kidney injury, Condition aggravated, Carpal tunnel syndrome, |
||||
SPIRONOLACTONE, FUROSEMIDE, OMEPRAZOLE, OMEPRAZOLE MAGNESIUM, BISOPROLOL FUMARATE, EMPAGLIFLOZIN, APIXABAN, APIXABAN, COLCHICINE, ALLOPURINOL, ACETAMINOPHEN, ACETAMINOPHEN 500MG, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, |
||||
| 119 | 26553122 |
EU |
88 | 2 |
Cardiac failure acute, Gastric cancer, Fluid intake reduced, Condition aggravated, Tachycardia, Muscular weakness, Fatigue, Nasopharyngitis, Obsessive-compulsive disorder, Mobility decreased, Vitamin B12 decreased, Chronic gastritis, |
||||
DICLOFENAC, DICLOFENAC SODIUM, AMLODIPINE, IBUPROFEN, IBUPROFEN CAPSULES 200 MG, IBUPROFEN TABLETS USP, 200MG, IBUPROFEN TABLET, FILM COATED, IBUPROFEN ORAL, IBUPROFEN 200MG, IBUPFROFEN, IBUPROFEN TABLET, FILM-COATED, IBUPROFEN 200 MG, IBUPROFEN CAPSULE, METOPROLOL TARTRATE, METOPROLOL, METOPROLOL TARTRATE, METOPROLOL, METOPROLOL TARTRATE, METOPROLOL, |
||||
| 120 | 26553461 |
|||
Abdominal pain, Hidradenitis, Condition aggravated, |
||||
BIMEKIZUMAB, |
||||
| 121 | 26553599 |
US |
2 | |
Condition aggravated, Off label use, |
||||
OMALIZUMAB, |
||||
| 122 | 26553661 |
EU |
44 | 2 |
Cholestasis, Condition aggravated, Jaundice, |
||||
ELAFIBRANOR, URSODIOL, URSOSIOL, |
||||
| 123 | 26553687 |
2 | ||
Rheumatoid arthritis, Polymyositis, Condition aggravated, Weight decreased, Nausea, Fatigue, Diarrhoea, |
||||
METHOTREXATE, METHOTREXATE SODIUM, UPADACITINIB, |
||||
| 124 | 26553720 |
EU |
63 | 2 |
Cellulitis, Ear infection, Malaise, Arthropod sting, Condition aggravated, Diarrhoea, Infection, Sinusitis, Oropharyngeal pain, Pharyngitis, SARS-CoV-2 test positive, Rhinorrhoea, Anosmia, |
||||
SECUKINUMAB, SECUKINUMAB, SECUKINUMAB, SECUKINUMAB, SECUKINUMAB, SECUKINUMAB, |
||||
| 125 | 26554018 |
CO |
35 | 1 |
Nephrolithiasis, Condition aggravated, |
||||
SEMAGLUTIDE, ORAL SEMAGLUTIDE, |
||||
| 126 | 26554087 |
US |
81 | 1 |
Peripheral swelling, Dyspnoea, Dyspnoea exertional, Condition aggravated, |
||||
ENSIFENTRINE, ENSIFENTRINE, FLUTICASONE FUROATE, UMECLIDINIUM BROMIDE AND VILANTEROL TRIFENATATE, FUROSEMIDE, |
||||
| 127 | 26554236 |
US |
58 | 2 |
Neuroborreliosis, Babesiosis, Condition aggravated, |
||||
PREDNISONE, PREDNISONE, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, DEXAMETHASONE, DEXAMETHASONE 1.5 MG, OXYCODONE, GABAPENTIN, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, ROSUVASTATIN, LOSARTAN, HYDROCHLOROTHIAZIDE, SERTRALINE, CLONAZEPAM, ACETAMINOPHEN, ACETAMINOPHEN 500MG, ACETAMINOPHEN TABLET EXTENDED RELEASE, PAIN RELIEVER, CYCLOBENZAPRINE, CELECOXIB, GABAPENTIN, |
||||
| 128 | 26554273 |
JP |
84 | 1 |
Dyspnoea, Diarrhoea, Pruritus, Condition aggravated, Peripheral coldness, Peripheral coldness, Abdominal distension, Chest discomfort, Decreased appetite, Feeding disorder, Abdominal pain upper, Taste disorder, Decreased appetite, Visual impairment, Dizziness, Nausea, Ligament sprain, Fall, Arthralgia, Bedridden, Dyspnoea, Dry skin, Vision blurred, |
||||
NINTEDANIB, NINTEDANIB, |
||||
| 129 | 26554347 |
ME |
63 | 2 |
Urosepsis, Abdominal pain, Clostridial infection, Urinary tract abscess, Dysuria, Condition aggravated, Lymphocyte count decreased, |
||||
SIPONIMOD, |
||||
| 130 | 26554386 |
US |
2 | |
Condition aggravated, |
||||
BENRALIZUMAB, BENRALIZUMAB, |
||||
| 131 | 26554455 |
EU |
1 | |
Condition aggravated, |
||||
| 132 | 26554869 |
CA |
59 | 1 |
Cardiac operation, Condition aggravated, Drug level below therapeutic, Off label use, |
||||
| 133 | 26555114 |
40 | ||
Hidradenitis, Condition aggravated, |
||||
BIMEKIZUMAB, |
||||
| 134 | 26555201 |
67 | ||
Restless legs syndrome, Condition aggravated, Product ineffective, |
||||
ROTIGOTINE, |
||||
| 135 | 26555222 |
US |
55 | 1 |
Disability, Concussion, Condition aggravated, Emotional disorder, Cerebral disorder, |
||||
UPADACITINIB, |
||||
| 136 | 26555247 |
EU |
88 | 2 |
Cardiac failure acute, Fatigue, Chronic gastritis, Condition aggravated, Fluid intake reduced, Tachycardia, Gastric cancer, Mobility decreased, Muscular weakness, Obsessive-compulsive disorder, Vitamin B12 decreased, Nasopharyngitis, |
||||
DICLOFENAC, DICLOFENAC SODIUM, AMLODIPINE BESYLATE, IBUPROFEN, IBUPROFEN CAPSULES 200 MG, IBUPROFEN TABLETS USP, 200MG, IBUPROFEN TABLET, FILM COATED, IBUPROFEN ORAL, IBUPROFEN 200MG, IBUPFROFEN, IBUPROFEN TABLET, FILM-COATED, IBUPROFEN 200 MG, IBUPROFEN CAPSULE, METOPROLOL SUCCINATE, METOPROLOL SUCCINATE ER TABLETS, METOPROLOL SUCCINATE, METOPROLOL SUCCINATE ER TABLETS, METOPROLOL SUCCINATE, METOPROLOL SUCCINATE ER TABLETS, |
||||
| 137 | 26558010 |
2 | ||
Pulmonary arterial hypertension, Condition aggravated, |
||||
| 138 | 26558213 |
2 | ||
Cystic fibrosis, Condition aggravated, Infection, Sleep disorder, Loss of personal independence in daily activities, |
||||
DORNASE ALFA, FLUOXETINE HYDROCHLORIDE, FLUOXETINE, |
||||
| 139 | 26558274 |
64 | 1 | |
Condition aggravated, Hypertrophic cardiomyopathy, Weight increased, Procedural pain, Fatigue, Pain, |
||||
MAVACAMTEN, CARVEDILOL, |
||||
| 140 | 26559194 |
55 | 2 | |
Acne, Condition aggravated, |
||||
UPADACITINIB, |
||||
| 141 | 26559891 |
62 | 2 | |
Diverticulitis, Chest discomfort, Diverticulum intestinal, Condition aggravated, |
||||
UPADACITINIB, GEMFIBROZIL, CIPROFLOXACIN, CIPROFLOXACIN HYDROCHLORIDE, CIPROFOLXACIN, CIPROFLOXACIN TABLETS, METRONIDAZOLE, METRONIDAZOLE TOPICAL, VALACYCLOVIR, VALACYCLOVIR HYDROCHLORIDE, ATENOLOL, BUPROPION, HYDROXYCHLOROQUINE, PREDNISONE, TERIPARATIDE, DOXYCYCLINE, DOXYCYCLINE HYCLATE, AMLODIPINE, CELECOXIB, GEMFIBROZIL, |
||||
| 142 | 26560182 |
|||
Suicidal ideation, Condition aggravated, |
||||
| 143 | 26565046 |
87 | 1 | |
Vestibular migraine, Constipation, Hypercalcaemia, Clonal cytopenia of undetermined significance, Condition aggravated, |
||||
LUSPATERCEPT, |
||||
| 144 | 26565202 |
21 | 2 | |
Condition aggravated, Insurance issue, Therapy interrupted, |
||||
USTEKINUMAB, |
||||
| 145 | 26565707 |
79 | 1 | |
Condition aggravated, |
||||
LENALIDOMIDE, |
||||
| 146 | 26569890 |
71 | 1 | |
Angioedema, Rash, Post-traumatic stress disorder, Condition aggravated, Blood pressure increased, Stress, Mood altered, Treatment noncompliance, Drug hypersensitivity, |
||||
LISINOPRIL, AMLODIPINE, HYDROXYCHLOROQUINE, |
||||
| 147 | 26548876 |
US |
65 | 2 |
Condition aggravated, Large intestinal stenosis, Platelet disorder, Hypophagia, Blood iron abnormal, |
||||
UPADACITINIB, |
||||
| 148 | 26548886 |
US |
||
Condition aggravated, Product dose omission issue, |
||||
GUSELKUMAB, GUSELKUMAB, GUSELKUMAB, GUSELKUMAB, |
||||
| 149 | 26548913 |
EU |
48 | 2 |
Leukopenia, Myelosuppression, Condition aggravated, |
||||
VALGANCICLOVIR HYDROCHLORIDE, VALGANCICLOVIR, VALGANCICLOVIR HYDROCHLORIDE POWDER,, MYCOPHENOLATE MOFETIL, MYCOPHENOLATE MOFETIL HYDROCHLORIDE, |
||||
| 150 | 26548971 |
EU |
88 | |
Sleep apnoea syndrome, Condition aggravated, |
||||
USTEKINUMAB-STBA, |
||||
| 151 | 26549145 |
US |
38 | 2 |
Condition aggravated, Inappropriate schedule of product administration, Product use in unapproved indication, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 152 | 26549148 |
US |
27 | 2 |
Condition aggravated, Product dose omission issue, |
||||
DUPILUMAB, |
||||
| 153 | 26549149 |
US |
29 | 1 |
Toothache, Condition aggravated, Intentional product misuse, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 154 | 26549206 |
US |
21 | 2 |
Condition aggravated, Product use in unapproved indication, |
||||
DUPILUMAB, DUPILUMAB, DUPILUMAB, |
||||
| 155 | 26549211 |
US |
39 | 1 |
Skin ulcer, Condition aggravated, Pruritus, Product dose omission in error, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 156 | 26549276 |
US |
58 | 2 |
Rash erythematous, Pruritus, Skin burning sensation, Condition aggravated, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 157 | 26549291 |
US |
20 | 2 |
Rash erythematous, Pruritus, Skin burning sensation, Condition aggravated, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 158 | 26549296 |
US |
37 | 2 |
Rash erythematous, Pruritus, Skin burning sensation, Condition aggravated, Product use in unapproved indication, |
||||
DUPILUMAB, |
||||
| 159 | 26549340 |
US |
6 | 2 |
Condition aggravated, |
||||
DUPILUMAB, |
||||
| 160 | 26549416 |
US |
1 | |
Nasal congestion, Product dose omission issue, Condition aggravated, |
||||
DUPILUMAB, |
||||
| 161 | 26549549 |
US |
55 | 2 |
Sinusitis, Hypersensitivity, Pruritus, Sinus polyp, Condition aggravated, Asthma, Incorrect dose administered, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 162 | 26549551 |
US |
54 | 1 |
Condition aggravated, Rash erythematous, Pruritus, Skin burning sensation, Product use in unapproved indication, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 163 | 26549651 |
US |
64 | 1 |
Ocular hyperaemia, Condition aggravated, |
||||
DUPILUMAB, |
||||
| 164 | 26549681 |
US |
35 | 1 |
Abdominal distension, Condition aggravated, Abdominal discomfort, Condition aggravated, Pain, |
||||
DUPILUMAB, |
||||
| 165 | 26549786 |
48 | ||
Hidradenitis, Condition aggravated, |
||||
BIMEKIZUMAB, |
||||
| 166 | 26549969 |
EU |
67 | 2 |
Anaemia, Condition aggravated, |
||||
TERIFLUNOMIDE, |
||||
| 167 | 26546822 |
US |
2 | |
Herpes zoster, Condition aggravated, |
||||
VIBEGRON, |
||||
| 168 | 26546862 |
US |
35 | 2 |
Rash erythematous, Pruritus, Skin burning sensation, Condition aggravated, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 169 | 26546916 |
US |
61 | 1 |
Nasopharyngitis, Pharyngeal swelling, Condition aggravated, Injection site pain, |
||||
DUPILUMAB, |
||||
| 170 | 26546953 |
US |
62 | 2 |
Flatulence, Condition aggravated, Vomiting, Pyrexia, Abdominal pain upper, Constipation, |
||||
DUPILUMAB, AMOXICILLIN, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, PSYLLIUM HUSK, CETIRIZINE HYDROCHLORIDE, |
||||
| 171 | 26547070 |
US |
1 | |
Eye pruritus, Condition aggravated, |
||||
DUPILUMAB, |
||||
| 172 | 26547149 |
US |
2 | |
Eye discharge, Ocular hyperaemia, Eye pain, Product size issue, Condition aggravated, |
||||
OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE, |
||||
| 173 | 26547234 |
|||
Injection site reaction, Hidradenitis, Condition aggravated, |
||||
BIMEKIZUMAB, ASPIRIN, ASPIRIN 81 MG, ASPIRIN 325 MG, |
||||
| 174 | 26547282 |
US |
56 | 2 |
Condition aggravated, Inappropriate schedule of product administration, Product use in unapproved indication, |
||||
DUPILUMAB, DUPILUMAB, ROSUVASTATIN, |
||||
| 175 | 26547341 |
US |
45 | 1 |
Dysphagia, Retching, Condition aggravated, |
||||
DUPILUMAB, |
||||
| 176 | 26547348 |
US |
2 | |
Nasal polyps, Condition aggravated, |
||||
DUPILUMAB, |
||||
| 177 | 26547356 |
US |
2 | |
Night sweats, Condition aggravated, Headache, Product adhesion issue, |
||||
ESTRADIOL, |
||||
| 178 | 26547492 |
|||
Hidradenitis, Condition aggravated, |
||||
BIMEKIZUMAB, |
||||
| 179 | 26547512 |
US |
||
Condition aggravated, |
||||
OLOPATADINE HYDROCHLORIDE, |
||||
| 180 | 26547530 |
US |
18 | 2 |
Idiopathic urticaria, Product dose omission issue, Condition aggravated, Rash erythematous, Pruritus, Skin burning sensation, |
||||
DUPILUMAB, FAMOTIDINE, |
||||
| 181 | 26547582 |
US |
10 | 1 |
Limb injury, Contusion, Condition aggravated, Haematoma, Condition aggravated, Peripheral swelling, Gait disturbance, |
||||
ANTIHEMOPHILIC FACTOR (RECOMBINANT), FC-VWF-XTEN FUSION PROTEIN-EHTL, ANTIHEMOPHILIC FACTOR (RECOMBINANT), FC-VWF-XTEN FUSION PROTEIN-EHTL, |
||||
| 182 | 26547612 |
US |
2 | |
Condition aggravated, |
||||
DUPILUMAB, |
||||
| 183 | 26547665 |
US |
1 | |
Condition aggravated, Eye irritation, Lacrimation increased, |
||||
OLOPATADINE HYDROCHLORIDE, |
||||
| 184 | 26547775 |
US |
65 | 2 |
Vision blurred, Eye pruritus, Condition aggravated, Product physical consistency issue, Liquid product physical issue, |
||||
OLOPATADINE HYDROCHLORIDE, |
||||
| 185 | 26547863 |
US |
2 | |
Drug ineffective, Condition aggravated, Asthenopia, Eye pain, Ocular discomfort, |
||||
OLOPATADINE HYDROCHLORIDE, OLOPATADINE HYDROCHLORIDE, |
||||
| 186 | 26547922 |
US |
45 | 2 |
Condition aggravated, |
||||
DUPILUMAB, |
||||
| 187 | 26547990 |
US |
60 | 1 |
Rash, Condition aggravated, Rash erythematous, Rash pruritic, Skin exfoliation, Skin discolouration, Skin laceration, Dermatitis, |
||||
DUPILUMAB, |
||||
| 188 | 26548027 |
US |
59 | 2 |
Condition aggravated, Drug ineffective, |
||||
ESTRADIOL, |
||||
| 189 | 26548119 |
46 | ||
Psoriasis, Hidradenitis, Condition aggravated, Off label use, |
||||
BIMEKIZUMAB, BIMEKIZUMAB, |
||||
| 190 | 26548201 |
US |
55 | 2 |
Nasal congestion, Nasal obstruction, Condition aggravated, Condition aggravated, Product use in unapproved indication, |
||||
DUPILUMAB, DUPILUMAB, |
||||
| 191 | 26548205 |
US |
||
Condition aggravated, Product substitution issue, |
||||
ESTRADIOL, |
||||
| 192 | 26548389 |
US |
56 | 2 |
Pneumonitis, Cough, Productive cough, Dyspnoea exertional, Pulmonary pain, Dyspnoea, Condition aggravated, Therapy non-responder, |
||||
OXYGEN, 0XYGEN, |
||||
| 193 | 26548407 |
US |
13 | 1 |
Rash pruritic, Condition aggravated, Product dose omission issue, |
||||
DUPILUMAB, DUPILUMAB, ALBUTEROL SULFATE, BUDESONIDE, EPINEPHRINE, OMEPRAZOLE MAGNESIUM, MONTELUKAST SODIUM, CETIRIZINE HYDROCHLORIDE, |
||||
| 194 | 26548495 |
45 | ||
Psoriasis, Hidradenitis, Condition aggravated, |
||||
BIMEKIZUMAB, BIMEKIZUMAB, |
||||
| 195 | 26548550 |
30 | ||
Hidradenitis, Condition aggravated, Product dose omission issue, |
||||
BIMEKIZUMAB, |
||||
| 196 | 26548628 |
US |
2 | |
Condition aggravated, |
||||
DUPILUMAB, ALBUTEROL SULFATE, ALBUTEROL, LISINOPRIL, MELOXICAM, MONTELUKAST SODIUM, CETIRIZINE HYDROCHLORIDE, ALBUTEROL SULFATE, ALBUTEROL, BUDESONIDE, GLYCOPYRROLATE, AND FORMOTEROL FUMARATE, PREDNISONE, |
||||
| 197 | 26548707 |
US |
16 | 1 |
Drug ineffective, Condition aggravated, |
||||
DUPILUMAB, |
||||
| 198 | 26548710 |
US |
54 | 2 |
Nasopharyngitis, Condition aggravated, Rhinorrhoea, Respiratory tract congestion, Injection site urticaria, Injection site erythema, Injection site swelling, Injection site warmth, Product use in unapproved indication, |
||||
DUPILUMAB, CALCIUM, CYCLOBENZAPRINE HYDROCHLORIDE, CYCLOBENZAPRINE, RALOXIFENE HYDROCHLORIDE, HYDROXYZINE HYDROCHLORIDE, HYDROXYZINE, HYDROXYZINE HYDROCHLORIDE ORAL, LINACLOTIDE, MAGNESIUM, ONDANSETRON HYDROCHLORIDE, ONDANSETRON, ONDANSETRON TABLETS, FAMOTIDINE, METOCLOPRAMIDE HYDROCHLORIDE, SPIRONOLACTONE, ACETAMINOPHEN, GUAIFENESIN, AND PHENYLEPHRINE HYDROCHLORIDE, ACETAMINOPHEN, ERGOCALCIFEROL, BUPROPION HYDROCHLORIDE, ALPRAZOLAM, |
||||
| 199 | 26548837 |
|||
Hidradenitis, Condition aggravated, Therapy interrupted, |
||||
BIMEKIZUMAB, |
||||
| 200 | 26552659 |
36 | 2 | |
Upper limb fracture, Psoriasis, Condition aggravated, Stress, Pustule, Injection site swelling, Injection site erythema, |
||||
GUSELKUMAB, |
||||
disclaimer
Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.
terms
license
last_updated
2026-04-28